Bayesian Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Bayesian Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,197	Closed	-$207K	–	918
2021 Q4	$207K	Buy	+15,197	New	+$213K	0.07%	318
2021 Q3	–	Sell	-14,222	Closed	-$239K	–	538
2021 Q2	$239K	Sell	14,222 -18,515	-57%	-$315K	0.06%	335
2021 Q1	$598K	Buy	32,737 +14,300	+78%	+$257K	0.14%	197
2020 Q4	$336K	Buy	18,437 +5,142	+39%	+$90.2K	0.09%	281
2020 Q3	$237K	Buy	+13,295	New	+$242K	0.06%	399
2020 Q2	–	Sell	-20,282	Closed	-$308K	–	774
2020 Q1	$308K	Buy	+20,282	New	+$368K	0.07%	447

Other funds holding TAK

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bayesian Capital Management's TAK Position: Q1 2022 in Review

Bayesian Capital Management sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 15,197 shares — an estimated $207K sold.

Bayesian Capital Management first reported a position in TAK in Q1 2020 and held it in 6 quarters. The position peaked at $598K in Q1 2021. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

Bayesian Capital Management reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Bayesian Capital Management sold 15,197 Takeda Pharmaceutical shares in Q1 2022, an estimated $207K.
Bayesian Capital Management first reported a position in Takeda Pharmaceutical in Q1 2020 and held it in 6 quarters.
Bayesian Capital Management's Takeda Pharmaceutical position peaked at $598K in Q1 2021.
288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on Bayesian Capital Management's 13F filing for Q1 2022, filed 16 May 2022.